In addition to the diagnostic role of our identified hub genes such as NKX2-2, KIT, BNDF, and TLE4 in CRC and its sub-types74,85–87, their roles in increasing CRC risk, tumor progression, and targeted therapy have been investigated. This evidence concerns the gene NKX2-2 and colorectal carcinoma.